« Back to Record
Citation APA

Wells, A. U., Flaherty, K. R., Brown, K., Inoue, Y., Devaraj, A., Richeldi, L., Moua, T., Crestani, B., Wuyts, W., Stowasser, S., Quaresma, M., Goeldner, R. G., Schlenker-Herceg, R., Bondue, B., INBUILD trial investigators,, & Kolb, M. (2020). Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. The Lancet. Respiratory medicine, 8(5), 453-460. doi:10.1016/S2213-2600(20)30036-9


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/305426

Wells, A. U., Flaherty, K. R., Brown, K., Inoue, Y., Devaraj, A., Richeldi, L., Moua, T., Crestani, B., Wuyts, W., Stowasser, S., Quaresma, M., Goeldner, R. G., Schlenker-Herceg, R., Bondue, B., INBUILD trial investigators,, & Kolb, M. (2020). Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. The Lancet. Respiratory medicine, 8(5), 453-460. doi:10.1016/S2213-2600(20)30036-9